State AIDS Drug Assistance Programs: Equity and efficiency in an era of rapidly changing treatment standards

Medical Care

Volumn 40, Issue 5, 2002, Pages 429-441

  Johri, Mira ^a,b   Paltiel, A David ^c   Goldie, Sue J ^d   Freedberg, Kenneth A ^d,e  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD CENTER FOR RISK ANALYSIS   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acquired immunodeficiency

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE COURSE; ECONOMICS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; INSURANCE; LIFE EXPECTANCY; MEDICAL CARE; MORTALITY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR; STANDARD; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIRECT SERVICE COSTS; DISEASE PROGRESSION; EFFICIENCY, ORGANIZATIONAL; ELIGIBILITY DETERMINATION; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; LIFE EXPECTANCY; MEDICAL ASSISTANCE; MODELS, ECONOMETRIC; ORGANIZATIONAL INNOVATION; QUALITY-ADJUSTED LIFE YEARS; STATE HEALTH PLANS; UNITED STATES;

EID: 0036584870     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200205000-00008     Document Type: Article

References (55)

1. Doyle A, Jefferys R, and Kelly J. State AIDS Drug Assistance Programs: A National Status Report on Access. 1997. Henry J. Kaiser Family Foundation.
2. Karon JM, Rosenberg PS, McQuillan G, et al. Prevalence of HIV infection in the United States, 1984 to 1992. JAMA 1996;276:126-131.
3. Holmberg SD. The estimated prevalence and incidence of HIV m 96 large US metropolitan areas. Am J Public Health 1996;86:642-654.
4. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 8 (2), 1-39. Atlanta, GA: National Center for HIV, STD and TB Prevention; 1996.
5. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 11(2), 1-44. Atlanta, GA: National Center for HIV, STD and TB Prevention; 1999.
6. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996;335:1081-1090.
7. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280:1497-1503.
8. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 1998;338:853-860.
9. The Panel on Clinical Practices for Treatment of HIV. Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, The Living Document. Available at: http://hivinsite.ucsf.edu/medical/ tx_guidelines/2098.3a62.html. Accessed 1/10/2001.
10. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-390.
11. Report to the Subcommittee on Labor, Health and Human Services and Education Committee on Appropriations US Senate. HIV/AIDS Drugs: Funding Implications of New Combination Therapies for Federal and State Programs. GAO/HEHS-99-2, 1-36.1998. Washington, DC, United States General Accounting Office.
12. Drug Topics Red Book. Medical economics data. Montvale, NJ: Medical Economics; 1999.
13. Doyle A, Jefferys R. National ADAP Monitoring Project: Annual Report, March 2000. Henry J. Kaiser Family Foundation.
14. Doyle A, Jefferys R, Kelly J, et al. National ADAP Monitoring Project: Annual Report, March 1999. Henry J. Kaiser Family Foundation.
15. Doyle A, Jefferys R, Kelly J. National ADAP Monitoring Project: Interim Technical Report, March 1998. Henry J. Kaiser Family Foundation.
16. Pear, R. Clinton to Seek More Money to Help Pay for AIDS Drugs. New York Times. December 30, 1997;A14.
17. Pear R. Expense means many can't get drugs for AIDS. New York Time. February 16, 1997;A1.
18. McGinnis JM. States move to ration promising AIDS drags. The Wall Street Journal. August 22, 1996;B1.
19. Green MJ, Fong S, Mauger DT, et al. Rationing HIV medications: What do patients and the public think all allocation policies? J Acquir Immune Defic Syndr Hum Retrovirol 2001;26:56-62.
20. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999;281:2305-2315.
21. Mole L, Ockrim K, Holodniy M. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. Pharmacoeconomics 1999;16:307-315.
22. Moore RD. Cost effectiveness of combination HIV therapy: 3 years later. Pharmacoeconomics 2000;17:325-330.
23. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999;13:963-969.
24. Keiser P, Kvanli MB, Turner D, et al. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:28-33.
25. Floridia M, Massella M, Bucciardini R, et al. Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4<50mm3). HIV Clinical Trials 2000;1:9-16.
26. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001;344:817-823.
27. Scharfstein JA, Paltiel AD, Weinstein MC, et al. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. Int J Technol Assess Health Care 1999;15:531-547.
28. Paltiel AD, Scharfstein JA, Seage GR, III, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Dec Making 1998;18:S93-105.
29. Paltiel AD, Goldie SJ, Losina E, et al. A pre-evaluation of clinical trial data: The case of preemptive CMV Therapy in HIV. Clin Infect Dis 2001;32: 783-793
30. Goldie SJ, Kaplan JE, Losina E. Current Issues in Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV: Using simulation modeling to inform clinical guidelines. Med Decis Making 1999.
31. Freedberg KA, Losina E, Weinstein MC, et al. The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. N Engl J Med 2001;344:824-831.
32. Weinstein MC, Goldie SJ, Losina E, et al. Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness. Ann Intern Med 2001;134:440-450.
33. US Bureau of the Census. Statistical Abstract of the United States: 1999. Washington, DC: US Bureau of the Census; 1999:119.
34. Gold MR, Siegel JE, Russell LB, et al. Cost Effectiveness in Health and Medicine. 1st Ed. Oxford: Oxford University Press; 1996.
35. Freedberg KA, Scharfstein JA, Seage GR, III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998;279:130-136.
36. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Infectious Diseases Society of America Ann Intern Med 1999;131:873-908.
37. USPHS/IDSA Prevention of Opportunistic Infections Working Group. US Public Health Services/ Infectious Diseases Society of America. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1997;25 Suppl 3:S313
38. 1997;35:S313-S335.
39. Gallant JE. Strategies for long-term success in the treatment of HIV infection. JAMA 2000;283:1329-1334.
40. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-1873.
41. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS. AIDS 2000;14:F83-F93.
42. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologie failure and adverse drug reactions. Ann Intern Med 1999;131:81-87.
43. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279:930-937.
44. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-733.
45. Multicenter AIDS Cohort Study (MACS) Public Data Set Release PO3. Springfield, VA, National Technical Information Survey, 1995.
46. Boston Medical Center, Office of Payment. Boston, MA. 2000.
47. Berk ML, Maffeo C, and Schur CL. Research design and analysis objectives. AIDS Costs and Services Utilization Survey (ACSUS) Report no.1. AHCPR Publication No. 93-0019. 1993. Rockville, MD, Agency for Health Care Policy and Research.
48. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998;339:1897-1904.
49. Paltiel AD, Stinnett AA. AIDS. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd Ed. New York, NY: Raven Press, 1996;1053-1062.
50. Goldman DP, Bhattacharya J, Leibowitz AA, et al. The impact of state policy on the costs of HIV infection. Med Care Res Rev 2001;58:31-53.
51. Trueman P, Youle M, Sabin CA, et al. The cost-effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United Kingdom. HIV Clinical Trials 2000;1:27-35.
52. Sendi PP, Bucher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study AIDS 1999;13:1115-1122.
53. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369-390.
54. Hays RD, Cunningham WE, Sherbourne CD, et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med 2000;108:714-722.
55. Schackman BS, Goldie SJ, Freedberg KA, et al. A comparison of health state utilities using community and patient preference weights derived from a survey of HIV/ AIDS patients. Med Decis Making 2001;In Press: